Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686712 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine at Bedtime or in AM Versus NPH
A Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT00686712 is a Phase 4 study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 108 participants.
The verdict
NCT00686712, a Phase 4 study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.
Interventions
- DRUG 1- Insulin glargine QHS
- DRUG 2 - Insulin glargine QAM
- DRUG 3 - NPH insulin QHS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686712
The ClinicalTrials.gov registry entry for NCT00686712 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Charles Drew University of Medicine and Science, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 1- Insulin glargine QHS is the first listed.
NCT00686712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686712 about?
NCT00686712 is a clinical study titled "Insulin Glargine at Bedtime or in AM Versus NPH". To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.
What is the current status of trial NCT00686712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2003-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00686712?
The interventions under investigation include: 1- Insulin glargine QHS (DRUG), 2 - Insulin glargine QAM (DRUG), 3 - NPH insulin QHS (DRUG).
Who is sponsoring clinical trial NCT00686712?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.